CUAMC
TARS icon

China Universal Asset Management Company’s Tarsus Pharmaceuticals TARS Stock Holding History

China Universal Asset Management Company’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Sell
6,847
-705
-9% -$45K 0.03% 277
2026
Q1 		$530K Buy
7,552
+635
+9% +$44.4K 0.04% 250
2025
Q4 		$566K Sell
6,917
-483
-7% -$36.1K 0.04% 248
2025
Q3 		$440K Sell
7,400
-1,038
-12% -$51.1K 0.04% 260
2025
Q2 		$342K Buy
8,438
+740
+10% +$33.3K 0.03% 275
2025
Q1 		$395K Sell
7,698
-408
-5% -$20.2K 0.04% 264
2024
Q4 		$449K Buy
8,106
+789
+11% +$35.8K 0.04% 260
2024
Q3 		$241K Buy
7,317
+2,879
+65% +$80.9K 0.03% 283
2024
Q2 		$121K Sell
4,438
-2,129
-32% -$71.6K 0.02% 290
2024
Q1 		$239K Buy
6,567
+2,735
+71% +$80.4K 0.03% 271
2023
Q4 		$77.6K Buy
3,832
+3,004
+363% +$50.2K 0.02% 315
2023
Q3 		$14.7K Buy
828
+476
+135% +$8.42K ﹤0.01% 319
2023
Q2 		$6.36K Sell
352
-10
-3% -$159 ﹤0.01% 347
2023
Q1 		$4.55K Buy
362
+91
+34% +$1.33K ﹤0.01% 373
2022
Q4 		$3.97K Buy
+271
New +$4.48K ﹤0.01% 321

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

China Universal Asset Management Company's TARS Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Tarsus Pharmaceuticals (TARS) stake by 9.3% in Q2 2026, selling an estimated $45K and leaving 6,847 shares worth $431K. The position accounts for 0.03% of the portfolio, ranked #277.

China Universal Asset Management Company first reported a position in TARS in Q4 2022 and has held it in 15 quarters since. The position peaked at $566K in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • China Universal Asset Management Company held 6,847 shares of Tarsus Pharmaceuticals worth $431K as of Q2 2026.
  • China Universal Asset Management Company sold 705 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $45K.
  • Tarsus Pharmaceuticals made up 0.03% of China Universal Asset Management Company's portfolio in Q2 2026, its #277 holding.
  • China Universal Asset Management Company first reported a position in Tarsus Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • China Universal Asset Management Company's Tarsus Pharmaceuticals position peaked at $566K in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.